4.6 Article

Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise

Journal

DIAGNOSTICS
Volume 12, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/diagnostics12010124

Keywords

cancer; immunotherapy; biomarker; microenvironment; microbiome; flow cytometry; cytokine

Ask authors/readers for more resources

Immune checkpoint inhibitors have changed the way cancer is treated but their effectiveness is limited and they can cause autoimmune side effects. Existing biomarkers are not sensitive or specific. This review discusses emerging tumor and immune tissue biomarkers and the impact of the gut microbiome on treatment outcomes.
Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of patients, even in the most responsive malignancies such as melanoma, and cause significant autoimmune side effects. Licenced biomarkers include tumour Programmed Death Ligand 1 expression by immunohistochemistry, microsatellite instability, and tumour mutational burden, none of which are particularly sensitive or specific. Emerging tumour and immune tissue biomarkers such as novel immunohistochemistry scores, tumour, stromal and immune cell gene expression profiling, and liquid biomarkers such as systemic inflammatory markers, kynurenine/tryptophan ratio, circulating immune cells, cytokines and DNA are discussed in this review. We also examine the influence of the faecal microbiome on treatment outcome and its use as a biomarker of response and toxicity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available